Top

Journal of Cardiovascular Translational Research

Published in:

28-09-2022 | Heart Failure | Review

Heart Failure with Preserved Ejection Fraction: Pathogenesis, Diagnosis, Exercise, and Medical Therapies

Authors: Qingyi Zhan, Wenjing Peng, Siqi Wang, Juan Gao

Published in: Journal of Cardiovascular Translational Research | Issue 2/2023

Abstract

Heart failure with preserved ejection fraction (HFpEF) accounts for more than one-half of total heart failure cases, with a high prevalence and poor prognosis, especially in older and female patients. Patients with HFpEF are characterized by hypertension, left ventricular hypertrophy, and diastolic dysfunction, and the main symptoms are dyspnea and exercise intolerance. HFpEF is currently poorly studied, and pharmacological treatment for HFpEF is still underexplored. Accumulating clinical trials have shown that exercise could exert benefits on diastolic dysfunction and quality of life in patients with HFpEF. However, there is a high limitation for applying exercise therapy due to exercise intolerance in patients with HFpEF. Key effectors of exercise-protection could be novel therapeutic targets for developing drugs to prevent and treat HFpEF. In this review article, we provide an overview of the pathogenic factors, diagnostic methods, research animal models, the mechanisms of exercise-mediated cardiac protection, and current treatments for HFpEF.

Graphical abstract

Simmonds SJ, Cuijpers I, Heymans S, Jones EAV. Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding. Cells. 2020;9(1):242. https://doi.org/10.3390/cells9010242.CrossRefPubMedPubMedCentral

Maeder MT, Rickli H. Heart failure with preserved left ventricular ejection fraction. Praxis (Bern 1994). 2013;102(21):1299–307. https://doi.org/10.1024/1661-8157/a001439.CrossRefPubMed

Ma C, Luo H, Fan L, Liu X, Gao C. Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis. Braz J Med Biol Res. 2020;53(7):e9646. https://doi.org/10.1590/1414-431X20209646.CrossRefPubMedPubMedCentral

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.PubMedCrossRef

Nunes RB, Alves JP, Kessler LP, Dal Lago P. Aerobic exercise improves the inflammatory profile correlated with cardiac remodeling and function in chronic heart failure rats. Clinics (Sao Paulo). 2013;68(6):876–82.PubMedCrossRef

Pandey A, Darden D, Berry JD. Low fitness in midlife: a novel therapeutic target for heart failure with preserved ejection fraction prevention. Prog Cardiovasc Dis. 2015;58(1):87–93.PubMedCrossRef

Leggio M, Fusco A, Loreti C, et al. Effects of exercise training in heart failure with preserved ejection fraction: an updated systematic literature review. Heart Fail Rev. 2020;25(5):703–11.PubMedCrossRef

Bernardo BC, Ooi JYY, Weeks KL, Patterson NL, McMullen JR. Understanding key mechanisms of exercise-induced cardiac protection to mitigate disease: current knowledge and emerging concepts. Physiol Rev. 2018;98(1):419–75.PubMedCrossRef

Jiang HK, Miao Y, Wang YH, et al. Aerobic interval training protects against myocardial infarction-induced oxidative injury by enhancing antioxidase system and mitochondrial biosynthesis. Clin Exp Pharmacol Physiol. 2014;41(3):192–201.PubMedCrossRef

10.

Stølen T, Shi M, Wohlwend M, et al. Effect of exercise training on cardiac metabolism in rats with heart failure. Scand Cardiovasc J. 2020;54(2):84–91.PubMedCrossRef

11.

Garza MA, Wason EA, Zhang JQ. Cardiac remodeling and physical training post myocardial infarction. World J Cardiol. 2015;7(2):52–64.PubMedPubMedCentralCrossRef

12.

Xing W, Li Y, Zhang H, et al. Improvement of vascular insulin sensitivity by downregulation of GRK2 mediates exercise-induced alleviation of hypertension in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2013;305(8):H1111–9. https://doi.org/10.1152/ajpheart.00290.2013.CrossRefPubMedPubMedCentral

13.

Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2016;315(1):36–46.PubMedPubMedCentralCrossRef

14.

Eaton CB, Pettinger M, Rossouw J, et al. Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multiracial cohort of postmenopausal women. Circ Heart Fail. 2016;9(10):e002883. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002883.CrossRefPubMedPubMedCentral

15.

Altara R, Giordano M, Nordén ES, et al. Targeting obesity and diabetes to treat heart failure with preserved ejection fraction. Front Endocrinol. 2017;8:160. https://doi.org/10.3389/fendo.2017.00160.CrossRef

16.

Warbrick I, Rabkin SW. Hypoxia-inducible factor 1-alpha (HIF-1alpha) as a factor mediating the relationship between obesity and heart failure with preserved ejection fraction. Obes Rev. 2019;20(5):701–12.PubMedCrossRef

17.

Kessler EL, Oerlemans MIFJ, van den Hoogen P, Yap C, Sluijter JPG, de Jager SCA. Immunomodulation in heart failure with preserved ejection fraction: current state and future perspectives. J Cardiovasc Transl Res. 2021;14(1):63–74.PubMedCrossRef

18.

Savji N, Meijers WC, Bartz TM, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC: Heart Fail. 2018;6(8):701–9.PubMed

19.

Hicklin HE, Gilbert ON, Ye F, Brooks JE, Upadhya B. Hypertension as a road to treatment of heart failure with preserved ejection fraction. Curr Hypertens Rep. 2020;22(10):82. https://doi.org/10.1007/s11906-020-01093-7.CrossRefPubMed

20.

Zhou G, Chen J, Wu C, et al. Deciphering the protein, modular connections and precision medicine for heart failure with preserved ejection fraction and hypertension based on TMT quantitative proteomics and molecular docking. Front Physiol. 2021;12:607089. https://doi.org/10.3389/fphys.2021.607089.CrossRefPubMedPubMedCentral

21.

Adamczak DM, Oduah MT, Kiebalo T, et al. Heart failure with preserved ejection fraction—a concise review. Curr Cardiol Rep. 2020;22(9):82. https://doi.org/10.1007/s11886-020-01349-3.CrossRefPubMedPubMedCentral

22.

Lin Y, Fu S, Yao Y, Li Y, Zhao Y, Luo L. Heart failure with preserved ejection fraction based on aging and comorbidities. J Transl Med. 2021;19(1):291. https://doi.org/10.1186/s12967-021-02935-x.CrossRefPubMedPubMedCentral

23.

Bustamante M, Garate-Carrillo A, Ito BR, et al. Unmasking of oestrogen-dependent changes in left ventricular structure and function in aged female rats: a potential model for pre-heart failure with preserved ejection fraction. J Physiol. 2019;597(7):1805–17.PubMedPubMedCentralCrossRef

24.

Sweeney M, Corden B, Cook SA. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle? EMBO Mol Med. 2020;12(10):e10865. https://doi.org/10.15252/emmm.201910865.CrossRefPubMedPubMedCentral

25.

Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2021;18(6):400–23.PubMedPubMedCentralCrossRef

26.

Jannapureddy S, Sharma M, Yepuri G, Schmidt AM, Ramasamy R. Aldose reductase: an emerging target for development of interventions for diabetic cardiovascular complications. Front Endocrinol. 2021;12:636267. https://doi.org/10.3389/fendo.2021.636267.CrossRef

27.

Mgbemena O, Zhang Y, Velarde G. Role of diabetes mellitus in heart failure with preserved ejection fraction: a review article. Cureus. 2021;13(11):e19398. https://doi.org/10.7759/cureus.19398.CrossRefPubMedPubMedCentral

28.

Gandhi PU, Gaggin HK, Redfield MM, et al. Insulin-like growth factor-binding protein-7 as a biomarker of diastolic dysfunction and functional capacity in heart failure with preserved ejection fraction: results from the RELAX trial. JACC: Heart Fail. 2016;4(11):860–9.PubMed

29.

Elsanhoury A, Nelki V, Kelle S, Van Linthout S, Tschöpe C. Epicardial fat expansion in diabetic and obese patients with heart failure and preserved ejection fraction—a specific HFpEF phenotype. Front Cardiovasc Med. 2021;8:720690. https://doi.org/10.3389/fcvm.2021.720690.CrossRefPubMedPubMedCentral

30.

Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297–317.PubMedCrossRef

31.

Harada T, Kagami K, Kato T, Ishii H, Obokata M. Exercise stress echocardiography in the diagnostic evaluation of heart failure with preserved ejection fraction. J Cardiovasc Dev Dis. 2022;9(3):87. https://doi.org/10.3390/jcdd9030087.CrossRefPubMedPubMedCentral

32.

Donal E, Lund LH, Oger E, et al. Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study. Eur Heart J Cardiovasc Imaging. 2016;17(1):106–13.PubMed

33.

Belyavskiy E, Morris DA, Url-Michitsch M, et al. Diastolic stress test echocardiography in patients with suspected heart failure with preserved ejection fraction: a pilot study. ESC Heart Fail. 2019;6(1):146–53.PubMedCrossRef

34.

Ezzatvar Y, Izquierdo M, Núñez J, Calatayud J, Ramírez-Vélez R, García-Hermoso A. Cardiorespiratory fitness measured with cardiopulmonary exercise testing and mortality in patients with cardiovascular disease: a systematic review and meta-analysis. J Sport Health Sci. 2021;10(6):609–19.PubMedPubMedCentralCrossRef

35.

Finet JE, Van Iterson EH, Wilson Tang WH. Invasive hemodynamic and metabolic evaluation of HFpEF. Curr Treat Options Cardiovasc Med. 2021;23(5):32. https://doi.org/10.1007/s11936-021-00904-7.CrossRefPubMedPubMedCentral

36.

Malhotra R, Bakken K, D’Elia E, Lewis GD. Cardiopulmonary exercise testing in heart failure. JACC: Heart Fail. 2016;4(8):607–16.PubMed

37.

Kaye DM, Wolsk E, Nanayakkara S, et al. Comprehensive physiological modeling provides novel insights into heart failure with preserved ejection fraction physiology. J Am Heart Assoc. 2021;10(19):e021584. https://doi.org/10.1161/JAHA.121.021584.CrossRefPubMedPubMedCentral

38.

Sorimachi H, Burkhoff D, Verbrugge FH, et al. Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23(10):1648–58.PubMedCrossRef

39.

Fudim M, Kaye DM, Borlaug BA, et al. Venous tone and stressed blood volume in heart failure: JACC review topic of the week. J Am Coll Cardiol. 2022;79(18):1858–69.PubMedCrossRef

40.

Plitt GD, Spring JT, Moulton MJ, Agrawal DK. Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction. Expert Rev Cardiovasc Ther. 2018;16(8):579–89.PubMedPubMedCentralCrossRef

41.

Seoudy H, von Eberstein M, Frank J, et al. HFA-PEFF score: prognosis in patients with preserved ejection fraction after transcatheter aortic valve implantation. ESC Heart Fail. 2022;9(2):1071–9.PubMedPubMedCentralCrossRef

42.

Sueta D, Yamamoto E, Nishihara T, et al. H2FPEF score as a prognostic value in HFpEF patients. Am J Hypertens. 2019;32(11):1082–90.PubMedCrossRef

43.

Dzhioeva O, Belyavskiy E. Diagnosis and management of patients with heart failure with preserved ejection fraction (HFpEF): current perspectives and recommendations. Ther Clin Risk Manag. 2020;16:769–85.PubMedPubMedCentralCrossRef

44.

Dubi S, Arbel Y. Large animal models for diastolic dysfunction and diastolic heart failure—a review of the literature. Cardiovasc Pathol. 2010;19(3):147–52.PubMedCrossRef

45.

Oktay AA, Shah SJ. Current perspectives on systemic hypertension in heart failure with preserved ejection fraction. Curr Cardiol Rep. 2014;16(12):545. https://doi.org/10.1007/s11886-014-0545-9.CrossRefPubMed

46.

Nakajima Y, Ito S, Asakura M, et al. A dipeptidyl peptidase-IV inhibitor improves diastolic dysfunction in Dahl salt-sensitive rats. J Mol Cell Cardiol. 2019;129:257–65.PubMedCrossRef

47.

Bowen TS, Eisenkolb S, Drobner J, et al. High-intensity interval training prevents oxidant-mediated diaphragm muscle weakness in hypertensive mice. FASEB J. 2017;31(1):60–71.PubMedCrossRef

48.

Khoury EE, Knaney Y, Fokra A, et al. Pulmonary, cardiac and renal distribution of ACE2, furin, TMPRSS2 and ADAM17 in rats with heart failure: potential implication for COVID-19 disease. J Cell Mol Med. 2021;25(8):3840–55.PubMedPubMedCentralCrossRef

49.

Shang L, Pin L, Zhu S, et al. Plantamajoside attenuates isoproterenol-induced cardiac hypertrophy associated with the HDAC2 and AKT/GSK-3beta signaling pathway. Chem Biol Interact. 2019;307:21–8.PubMedCrossRef

50.

Goto K, Schauer A, Augstein A, et al. Muscular changes in animal models of heart failure with preserved ejection fraction: what comes closest to the patient? ESC Heart Fail. 2021;8(1):139–50.PubMedCrossRef

51.

Riehle C, Bauersachs J. Of mice and men: models and mechanisms of diabetic cardiomyopathy. Basic Res Cardiol. 2018;114(1):2. https://doi.org/10.1007/s00395-018-0711-0.CrossRefPubMedPubMedCentral

52.

Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13(1):18–28.PubMedCrossRef

53.

Valero-Muñoz M, Backman W, Sam F. Murine models of heart failure with preserved ejection fraction: a “fishing expedition.” JACC: Basic to Transl Sci. 2017;2(6):770–89.

54.

Schiattarella GG, Altamirano F, Tong D, et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature. 2019;568(7752):351–6.PubMedPubMedCentralCrossRef

55.

Koch SE, Haworth KJ, Robbins N, et al. Age- and gender-related changes in ventricular performance in wild-type FVB/N mice as evaluated by conventional and vector velocity echocardiography imaging: a retrospective study. Ultrasound Med Biol. 2013;39(11):2034–43.PubMedPubMedCentralCrossRef

56.

Karuppagounder V, Arumugam S, Babu SS, et al. The senescence accelerated mouse prone 8 (SAMP8): a novel murine model for cardiac aging. Ageing Res Rev. 2017;35:291–6.PubMedCrossRef

57.

Charles CJ, Lee P, Li RR, et al. A porcine model of heart failure with preserved ejection fraction: magnetic resonance imaging and metabolic energetics. ESC Heart Fail. 2020;7(1):92–102.PubMed

58.

Wallner M, Eaton DM, Berretta RM, et al. A feline HFpEF model with pulmonary hypertension and compromised pulmonary function. Sci Rep. 2017;7(1):16587. https://doi.org/10.1038/s41598-017-15851-2.CrossRefPubMedPubMedCentral

59.

Charles CJ, Rademaker MT, Scott NJA, Richards AM. Large animal models of heart failure: reduced vs. preserved ejection fraction. Animals (Basel). 2020;10(10):1906. https://doi.org/10.3390/ani10101906.CrossRefPubMed

60.

Munagala VK, Hart CY, Burnett JC Jr, Meyer DM, Redfield MM. Ventricular structure and function in aged dogs with renal hypertension: a model of experimental diastolic heart failure. Circulation. 2005;111(9):1128–35.PubMedPubMedCentralCrossRef

61.

Bei Y, Wang L, Ding R, et al. Animal exercise studies in cardiovascular research: current knowledge and optimal design—a position paper of the Committee on Cardiac Rehabilitation, Chinese Medical Doctors’ Association. J Sport Health Sci. 2021;10(6):660–74.PubMedPubMedCentralCrossRef

62.

Edelmann F, Gelbrich G, Düngen HD, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (exercise training in diastolic heart failure) pilot study. J Am Coll Cardiol 2011;58(17):1780–91.

63.

Kitzman DW, Brubaker PH, Herrington DM, et al. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. J Am Coll Cardiol. 2013;62(7):584–92.PubMedPubMedCentralCrossRef

64.

Houstis NE, Eisman AS, Pappagianopoulos PP, et al. Exercise intolerance in heart failure with preserved ejection fraction: diagnosing and ranking its causes using personalized O2 pathway analysis. Circulation. 2018;137(2):148–61.PubMedCrossRef

65.

Guo J, Wang Z, Wu J, et al. Endothelial SIRT6 is vital to prevent hypertension and associated cardiorenal injury through targeting Nkx3.2-GATA5 signaling. Circ Res. 2019;124(10):1448–61.PubMedCrossRef

66.

Gladden JD, Chaanine AH, Redfield MM. Heart failure with preserved ejection fraction. Annu Rev Med. 2018;69:65–79.PubMedCrossRef

67.

Gao J, Pan X, Li G, Chatterjee E, Xiao J. Physical exercise protects against endothelial dysfunction in cardiovascular and metabolic diseases. J Cardiovasc Transl Res. 2022;15(3):604–20. https://doi.org/10.1007/s12265-021-10171-3.

68.

Bowen TS, Rolim NP, Fischer T, et al. Heart failure with preserved ejection fraction induces molecular, mitochondrial, histological, and functional alterations in rat respiratory and limb skeletal muscle. Eur J Heart Fail. 2015;17(3):263–72.PubMedCrossRef

69.

Liu J, Ji XX, Fu Y, et al. Early passive leg movement prevents against the development of heart failure with preserved ejection fraction in rats. Front Cardiovasc Med. 2021;8:655009. https://doi.org/10.3389/fcvm.2021.655009.CrossRefPubMedPubMedCentral

70.

Adams V, Alves M, Fischer T, et al. High-intensity interval training attenuates endothelial dysfunction in a Dahl salt-sensitive rat model of heart failure with preserved ejection fraction. J Appl Physiol(1985). 2015;119(6):745–52.PubMedCrossRef

71.

Schmederer Z, Rolim N, Bowen TS, et al. Endothelial function is disturbed in a hypertensive diabetic animal model of HFpEF: moderate continuous vs. high intensity interval training. Int J Cardiol. 2018;273:147–54.PubMedCrossRef

72.

Shen X, Tan Z, Zhong X, et al. Endocardial endothelium is a key determinant of force-frequency relationship in rat ventricular myocardium. J Appl Physiol(1985). 2013;115(3):383–93.PubMedCrossRef

73.

Zeng H, Chen JX. Microvascular rarefaction and heart failure with preserved ejection fraction. Front Cardiovasc Med. 2019;6:15. https://doi.org/10.3389/fcvm.2019.00015.CrossRefPubMedPubMedCentral

74.

Sandri M, Viehmann M, Adams V, et al. Chronic heart failure and aging — effects of exercise training on endothelial function and mechanisms of endothelial regeneration: results from the Leipzig Exercise Intervention in Chronic heart failure and Aging (LEICA) study. Eur J Prev Cardiol. 2016;23(4):349–58.PubMedCrossRef

75.

Machado MV, Martins RL, Borges J, et al. Exercise training reverses structural microvascular rarefaction and improves endothelium-dependent microvascular reactivity in rats with diabetes. Metab Syndr Relat Disord. 2016;14(6):298–304.PubMedCrossRef

76.

Machado MV, Vieira AB, da Conceição FG, Nascimento AR, da Nóbrega ACL, Tibirica E. Exercise training dose differentially alters muscle and heart capillary density and metabolic functions in an obese rat with metabolic syndrome. Exp Physiol. 2017;102(12):1716–28.PubMedCrossRef

77.

DA Silva ND Jr, Fernandes T, Soci UP, Monteiro AW, Phillips MI, DE Oliveira EM. Swimming training in rats increases cardiac microRNA-126 expression and angiogenesis. Med Sci Sports Exerc. 2012;44(8):1453-62.https://doi.org/10.1249/MSS.0b013e31824e8a36.

78.

Wang L, Wang J, Cretoiu D, Li G, Xiao J. Exercise-mediated regulation of autophagy in the cardiovascular system. J Sport Health Sci. 2020;9(3):203–10.PubMedCrossRef

79.

van Heerebeek L, Hamdani N, Falcão-Pires I, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126(7):830–9.PubMedCrossRef

80.

Slater RE, Strom JG, Granzier H. Effect of exercise on passive myocardial stiffness in mice with diastolic dysfunction. J Mol Cell Cardiol. 2017;108:24–33.PubMedCrossRef

81.

Hidalgo C, Saripalli C, Granzier HL. Effect of exercise training on post-translational and post-transcriptional regulation of titin stiffness in striated muscle of wild type and IG KO mice. Arch Biochem Biophys. 2014;552–553:100–7.PubMedCrossRef

82.

Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131(6):550–9. https://doi.org/10.1161/CIRCULATIONAHA.114.009625.CrossRefPubMed

83.

Dong S, Ma W, Hao B, et al. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int J Clin Exp Pathol. 2014;7(2):565–74.PubMedPubMedCentral

84.

Alves JP, Nunes RB, Ferreira DDC, Stefani GP, Jaenisch RB, Lago PD. High-intensity resistance training alone or combined with aerobic training improves strength, heart function and collagen in rats with heart failure. Am J Transl Res. 2017;9(12):5432–41.PubMedPubMedCentral

85.

Cuijpers I, Simmonds SJ, van Bilsen M, et al. Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities. Basic Res Cardiol. 2020;115(4):39. https://doi.org/10.1007/s00395-020-0798-y.CrossRefPubMedPubMedCentral

86.

Lee Y, Kwak HB, Hord J, Kim JH, Lawler JM. Exercise training attenuates age-dependent elevation of angiotensin II type 1 receptor and Nox2 signaling in the rat heart. Exp Gerontol. 2015;70:163–73.PubMedCrossRef

87.

Hieda M, Sarma S, Hearon CM Jr, et al. One-year committed exercise training reverses abnormal left ventricular myocardial stiffness in patients with stage B heart failure with preserved ejection fraction. Circulation. 2021;144(12):934–46.PubMedPubMedCentralCrossRef

88.

Johnson EJ, Dieter BP, Marsh SA. Evidence for distinct effects of exercise in different cardiac hypertrophic disorders. Life Sci. 2015;123:100–6.PubMedCrossRef

89.

Fujimoto N, Prasad A, Hastings JL, et al. Cardiovascular effects of 1 year of progressive endurance exercise training in patients with heart failure with preserved ejection fraction. Am Heart J. 2012;164(6):869–77.PubMedCrossRef

90.

Heinzel FR, Hohendanner F, Jin G, Sedej S, Edelmann F. Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. J Appl Physiol(1985). 2015;119(10):1233–42.PubMedCrossRef

91.

Vega RB, Konhilas JP, Kelly DP, Leinwand LA. Molecular mechanisms underlying cardiac adaptation to exercise. Cell Metab. 2017;25(5):1012–26.PubMedPubMedCentralCrossRef

92.

Tong D, Schiattarella GG, Jiang N, et al. NAD(+) repletion reverses heart failure with preserved ejection fraction. Circ Res. 2021;128(11):1629–41.PubMedPubMedCentralCrossRef

93.

Roh JD, Houstis N, Yu A, et al. Exercise training reverses cardiac aging phenotypes associated with heart failure with preserved ejection fraction in male mice. Aging Cell. 2020;19(6):e13159. https://doi.org/10.1111/acel.13159.CrossRefPubMedPubMedCentral

94.

Campion D, Charbonnier C, Nicolas G. SORL1 genetic variants and Alzheimer disease risk: a literature review and meta-analysis of sequencing data. Acta Neuropathol. 2019;138(2):173–86.PubMedCrossRef

95.

Ma QL, Galasko DR, Ringman JM, et al. Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid. Arch Neurol. 2009;66(4):448–57.PubMedPubMedCentralCrossRef

96.

Nowak KJ, Wattanasirichaigoon D, Goebel HH, et al. Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy. Nat Genet. 1999;23(2):208–12.PubMedCrossRef

97.

Castro V, Grisdale-Helland B, Helland SJ, et al. Cardiac molecular-acclimation mechanisms in response to swimming-induced exercise in Atlantic salmon. PLoS ONE. 2013;8(1):e55056. https://doi.org/10.1371/journal.pone.0055056.CrossRefPubMedPubMedCentral

98.

Papademetriou V, Toumpourleka M, Imprialos KP, Alataki S, Manafis A, Stavropoulos K. The role of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction. Curr Pharm Des. 2018;24(46):5517–24.PubMedCrossRef

99.

Qamer SZ, Malik A, Bayoumi E, et al. Digoxin use and outcomes in patients with heart failure with reduced ejection fraction. Am J Med. 2019;132(11):1311–9.PubMedCrossRef

100.

Ilieșiu AM, Hodorogea AS. Treatment of heart failure with preserved ejection fraction. Adv Exp Med Biol. 2018;1067:67–87.PubMedCrossRef

101.

Oelze M, Knorr M, Kröller-Schön S, et al. Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression. Eur Heart J. 2013;34(41):3206–16.PubMedCrossRef

102.

Wagdy K, Hassan M. NEAT HFpEF: organic nitrates fail to deliver. Glob Cardiol Sci Pract. 2016;2016(1):e201601. https://doi.org/10.21542/gcsp.2016.1.CrossRefPubMedPubMedCentral

103.

Borlaug BA, Anstrom KJ, Lewis GD, et al. Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial. J Am Med Assoc. 2018;320(17):1764–73.CrossRef

104.

Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017;38(15):1119–27.PubMedPubMedCentralCrossRef

105.

Armstrong PW, Lam CSP, Anstrom KJ, et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. J Am Med Assoc. 2020;324(15):1512–21.CrossRef

106.

Redfield MM, Borlaug BA, Lewis GD, et al. PhosphdiesteRasE-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial: rationale and design. Circ Heart Fail. 2012;5(5):653–9.PubMedPubMedCentralCrossRef

107.

Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. J Am Med Assoc. 2013;309(12):1268–77.CrossRef

108.

Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Cardiac Fail. 2017;23(8):628–51.CrossRef

109.

Noble D, Noble PJ. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart. 2006;92(Suppl 4):iv1–5. https://doi.org/10.1136/hrt.2005.078782.CrossRefPubMedPubMedCentral

110.

Maier LS, Layug B, Karwatowska-Prokopczuk E, et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC: Heart Fail. 2013;1(2):115–22. https://doi.org/10.1016/j.jchf.2012.12.002.CrossRefPubMed

111.

Pitt B. Heart failure: the role for mineralocorticoid receptor antagonists. Swiss Med Wkly. 2014;144:w13959. https://doi.org/10.4414/smw.2014.13959.CrossRefPubMed

112.

Fudim M, Kelly JP, Brophy TJ, et al. Trends in treatment for patients hospitalized with heart failure with preserved ejection fraction before and after treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Am J Cardiol. 2020;125(11):1655–60.PubMedCrossRef

113.

Belkin MN, Blair JE, Shah SJ, Alenghat FJ. A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction. ESC Heart Fail. 2021;8(5):3495–503.PubMedPubMedCentralCrossRef

114.

Salah HM, Verma S, Santos-Gallego CG, et al. Sodium-glucose cotransporter 2 inhibitors and cardiac remodeling. J Cardiovasc Transl Res. 2022. https://doi.org/10.1007/s12265-022-10220-5.CrossRefPubMed

115.

Packer M, Anker SD, Butler J, et al. Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-reduced trial. J Am Coll Cardiol. 2021;77(11):1381–92.PubMedCrossRef

116.

Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15. https://doi.org/10.1186/s12933-019-0816-2.CrossRefPubMedPubMedCentral

117.

Vashi R, Patel BM. NRF2 in cardiovascular diseases: a ray of hope! J Cardiovasc Transl Res. 2021;14(3):573–86.PubMedCrossRef

118.

Xia Q, Campbell JA, Ahmad H, Si L, de Graaff B, Palmer AJ. Bariatric surgery is a cost-saving treatment for obesity—a comprehensive meta-analysis and updated systematic review of health economic evaluations of bariatric surgery. Obes Rev. 2020;21(1):e12932. https://doi.org/10.1111/obr.12932.CrossRefPubMed

119.

Jensterle M, Janež A. Glucagon like peptide 1 receptor agonists in the treatment of obesity. Horm Res Paediatr. 2021.https://doi.org/10.1159/000521264.

120.

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.PubMedCrossRef

121.

Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–84.PubMedCrossRef

122.

Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. J Am Med Assoc. 2021;325(14):1403–13.CrossRef

123.

Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. J Am Med Assoc. 2021;325(14):1414–25.CrossRef

124.

Bakbak E, Terenzi DC, Trac JZ, et al. Lessons from bariatric surgery: can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease? Rev Endocr Metab Disord. 2021;22(4):1171–88.PubMedCrossRef

125.

Xiao J, Rosenzweig A. Exercise and cardiovascular protection: update and future. J Sport Health Sci. 2021;10(6):607–8.PubMedPubMedCentralCrossRef

126.

Adamopoulos S, Parissis J, Kroupis C, et al. Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur Heart J. 2001;22(9):791–7.PubMedCrossRef

127.

Bei Y, Huang Z, Feng X, et al. Lymphangiogenesis contributes to exercise-induced physiological cardiac growth. J Sport Health Sci. 2022;S2095–2546(22):00037. https://doi.org/10.1016/j.jshs.2022.02.005.CrossRef

128.

Church TS, Earnest CP, Skinner JS, Blair SN. Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: a randomized controlled trial. JAMA. 2007;297(19):2081–91.PubMedCrossRef

Title: Heart Failure with Preserved Ejection Fraction: Pathogenesis, Diagnosis, Exercise, and Medical Therapies
Authors: Qingyi Zhan
Wenjing Peng
Siqi Wang
Juan Gao
Publication date: 28-09-2022
Publisher: Springer US
Keyword: Heart Failure
Published in: Journal of Cardiovascular Translational Research / Issue 2/2023
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-022-10324-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Heart Failure with Preserved Ejection Fraction: Pathogenesis, Diagnosis, Exercise, and Medical Therapies

Abstract

Graphical abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Graphical abstract

Please log in to get access to this content

Other articles of this Issue 2/2023

Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte Ratios, and Systemic Immune-Inflammation Index as Predictors of Mortality in Coronary Artery Disease

Dkk1: a Putative Protector Against Vascular Calcification

Role of Pyruvate Kinase M2 (PKM2) in Cardiovascular Diseases

Chronic Oxidative Stress as a Marker of Long-term Radiation-Induced Cardiovascular Outcomes in Breast Cancer

Roles of TRPV4 in Regulating Circulating Angiogenic Cells to Promote Coronary Microvascular Regeneration

tRNA-Derived Small RNAs: Novel Insights into the Pathogenesis and Treatment of Cardiovascular Diseases